Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity

Research output: Contribution to journalLetterResearchpeer-review

DOI

  1. In vivo and in vitro characterization of GL0034, a novel long-acting glucagon-like peptide-1 receptor agonist

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The effect of curcumin on hepatic fat content in individuals with obesity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diagnostic and prognostic value of the electrocardiogram in stable outpatients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Liraglutide versus colesevelam for treating bile acid diarrhoea – Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

    Research output: Contribution to journalComment/debateResearchpeer-review

  5. Mapping prohormone processing by proteases in human enteroendocrine cells using genetically engineered organoid models

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

AIMS: When combined with glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonism, antagonising the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) reduces body weight in rodent models of obesity. Here, we investigated the acute effects of GIPR antagonism combined with a GLP-1 infusion on determinants of body weight in patients with type 2 diabetes and overweight/obesity.

MATERIALS AND METHODS: In a randomised, double-blind, placebo-controlled, crossover design, human synthetic GLP-1(7-36)NH2 (0.75 pmol/kg/min) was infused together with the selective GIPR antagonist GIP(3-30)NH2 (1,200 pmol/kg/min) or placebo for 320 minutes on two separate days covering an initial oral liquid mixed meal test and a terminal ad libitum meal. Appetite sensations, resting energy expenditure (REE) and food intake were evaluated, and subcutaneous adipose tissue (SAT) biopsies were analysed for triglyceride content.

RESULTS: Ten patients with type 2 diabetes and overweight/obesity (mean±SD; HbA1c 52±9 mmol/mol (7±1%); BMI 32.5±4.8 kg/m2 ) were included. Compared to placebo, infusion of the GIPR antagonist GIP(3-30)NH2 added to a GLP-1 infusion had no effect on appetite sensations, REE, food intake, or SAT triglyceride content during an ad libitum meal. Compared to placebo, GIP(3-30)NH2 lowered plasma glucagon by -12.4±5.9% (p=0.037), and reduced serum insulin by -32.5±8.0% (p=0.027).

CONCLUSIONS: During short term infusion, we found no effect of GIPR antagonism added to GLP-1R agonism on appetite sensations, REE, SAT triglyceride content or food intake in patients with type 2 diabetes and overweight/obesity. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume24
Issue number9
Pages (from-to)1882-1887
Number of pages6
ISSN1462-8902
DOIs
Publication statusPublished - Sep 2022

Bibliographical note

This article is protected by copyright. All rights reserved.

    Research areas

  • Appetite, Diabetes Mellitus, Type 2/complications, Eating, Energy Metabolism, Gastric Inhibitory Polypeptide/metabolism, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Humans, Incretins, Obesity/complications, Overweight/complications, Receptors, Gastrointestinal Hormone

ID: 77661619